Free Trial
NASDAQ:YMAB

Y-mAbs Therapeutics Q2 2025 Earnings Report

Y-mAbs Therapeutics logo
$8.57 -0.01 (-0.12%)
Closing price 04:00 PM Eastern
Extended Trading
$8.57 0.00 (0.00%)
As of 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Y-mAbs Therapeutics EPS Results

Actual EPS
-$0.07
Consensus EPS
-$0.27
Beat/Miss
Beat by +$0.20
One Year Ago EPS
N/A

Y-mAbs Therapeutics Revenue Results

Actual Revenue
$19.52 million
Expected Revenue
$18.40 million
Beat/Miss
Beat by +$1.12 million
YoY Revenue Growth
N/A

Y-mAbs Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Friday, August 8, 2025
Conference Call Time
9:30AM ET

Upcoming Earnings

Y-mAbs Therapeutics' Q3 2025 earnings is scheduled for Friday, November 14, 2025, with a conference call scheduled on Friday, November 7, 2025 at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Y-mAbs Therapeutics Earnings Headlines

Brokerages Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) PT at $9.62
What Steve Bannon revealed about Trump’s gold play
A Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your IRA could be at risk. Here’s how to prepare.tc pixel
See More Y-mAbs Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Y-mAbs Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Y-mAbs Therapeutics and other key companies, straight to your email.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics (NASDAQ:YMAB) is a clinical‐stage biopharmaceutical company focused on developing antibody-based cancer immunotherapies for pediatric and adult patients. Leveraging proprietary antibody engineering and radiolabeling platforms, the company targets solid tumors and central nervous system malignancies that express the GD2 antigen. Its research approach combines monoclonal antibodies with radioconjugates to selectively deliver therapeutic payloads to cancer cells.

The company’s lead product, DANYELZA (naxitamab-gqgk), received U.S. Food and Drug Administration approval in 2020 for the treatment of high-risk neuroblastoma in pediatric and young adult patients whose disease has not progressed after multi-cycle chemotherapy. In addition to its marketed therapy, Y-mAbs is advancing omburtamab, a radiolabeled monoclonal antibody designed to target metastatic or leptomeningeal tumors in the central nervous system. The pipeline also includes earlier-stage antibody candidates exploring novel targets in solid tumors.

Headquartered in New York, Y-mAbs is domiciled in Switzerland and conducts clinical trials across North America, Europe and Australia. Commercial operations for DANYELZA extend into the United States and Canada, with expanded access programs facilitating treatment for patients outside traditional trial settings. Through collaborations with leading research institutions, the company continues to broaden its development footprint in pediatric oncology.

Founded in 2016 out of collaborative research efforts, Y-mAbs operates under a management team with extensive experience in oncology drug development and regulatory strategy. The company’s scientific leadership and board comprise veterans of both large-cap pharmaceutical firms and specialized biotech startups, supporting its mission to bring targeted immunotherapies to underserved cancer populations.

View Y-mAbs Therapeutics Profile

More Earnings Resources from MarketBeat